- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Wockhardt submitted a US FDA New Drug Application for Zidebactam-Cefepime (ZAYNICH™), a novel antibiotic targeting serious Gram-negative infections. This milestone is significant as the first fully Indian-developed drug to reach US FDA NDA stage, addressing critical multi-drug resistant pathogens.